EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)

Courtney Levy, Sarah Sauchelli, Jessica L Abel, Mia Wraight, Dorothee Oberdhan, Lynda Doward, Ari Gnanasakthy

Value in Health · 2026

DOI: 10.1016/j.jval.2026.04.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Courtney Levy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Patient-Centered Outcomes Assessment, RTI Health Solutions, Manchester, England, UK. Electronic address: clevy@rti.org. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Drug Approval. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc, Jazz Pharmaceuticals Inc Ewing, Otsuka America Pharmaceutical Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Inclusion of patient-reported outcome (PRO) data in Summaries of Product Characteristics (SmPCs) and package leaflets published by the European Medicines Agency (EMA) is critical to communicate patient-reported value of new medicines. This study aimed to identify key issues in the incorporation and interpretation of PROs in clinical trials that may hinder approval of PRO-related language in SmPCs/package leaflets. METHODS: Indications of new medicines recommended for approval by the EMA between 2020 and 2023 were identified. The Public Assessment Reports, SmPCs, and package leaflets were systematically reviewed. Information pertaining to inclusion of PROs in confirmatory trial(s) and PRO-related reviewer comments were extracted and categorized. RESULTS: Of 167 indications examined, 58 (35%) included PRO-related statements of treatment effect in the SmPC/package leaflet. Critical comments by EMA reviewers focused on study design and PRO data robustness, concerns about statistical analysis, data quality, and PRO measure appropriateness. Such critiques did not always lead to exclusion of PROs from the SmPC, particularly when PRO endpoints were multiplicity-controlled. PRO data collected in unblinded trials-sometimes unavoidable-were often deemed acceptable if multiplicity-controlled. CONCLUSIONS: Review findings emphasize that thoughtful selection of PRO measures, their implementation in trial protocol design, and appropriate statistical analysis planning can strengthen the credibility of PRO results in confirmatory trials, which is critical for supporting the approval of PRO-based value messaging. Insights generated may be used by marketing authorization applicants to support a favorable assessment of PRO data by the EMA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresDrug ApprovalHumansEuropeClinical Trials as TopicResearch Design

Stichwörter der Autor:innen

European Medicines Agency (EMA)Patient-reported outcome (PRO)Summary of Product Characteristics (SmPC)clinical trialspackage leafletpatient-reported outcome measure (PROM)

Autor:innen und Institutionen

  • Patient-Centered Outcomes Assessment, RTI Health Solutions, Manchester, England, UK. Electronic address: clevy@rti.org.
  • Patient-Centered Outcomes Assessment, RTI Health Solutions, Manchester, England, UK.
  • Patient-Centered Outcomes Research, AbbVie Inc, Florham Park, NJ, USA.
  • Patient-Centered Outcomes, Jazz Pharmaceuticals, Palo Alto, CA, USA.
  • Global Integrated Evidence and Innovation, Otsuka Pharmaceutical Development and Commercialization, Inc, Rockville, MD, USA.
  • Patient-Centered Outcomes Assessment, RTI Health Solutions, Durham, NC, USA.

Förderung

  • AbbVie Inc
  • Jazz Pharmaceuticals Inc Ewing
  • Otsuka America Pharmaceutical Inc

Zitieren

APA

Levy, C., Sauchelli, S., Abel, J. L., Wraight, M., Oberdhan, D., Doward, L., & Gnanasakthy, A. (2026). Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health. https://doi.org/10.1016/j.jval.2026.04.017

Vancouver

Levy C, Sauchelli S, Abel JL, Wraight M, Oberdhan D, Doward L, et al. Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health. 2026. doi:10.1016/j.jval.2026.04.017

BibTeX
@article{Levy2026,
  author = {Levy, Courtney and Sauchelli, Sarah and Abel, Jessica L and Wraight, Mia and Oberdhan, Dorothee and Doward, Lynda and Gnanasakthy, Ari},
  title = {Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)},
  journal = {Value in Health},
  year = {2026},
  doi = {10.1016/j.jval.2026.04.017}
}
Kostenlos starten →